Immuno-Oncology | Specialty

Emerging I-O Combination Trials in Unresectable HCC

February 1st 2020

IMbrave150 in Unresectable HCC

February 1st 2020

Immunotherapy in Unresectable HCC

February 1st 2020

Challenges With Novel Treatment Strategies

February 1st 2020

The COSMIC-312 Phase III and Other Notable Trials

February 1st 2020

IMbrave150 Phase III Design, Results, and Practical Implications

February 1st 2020

The Impact of Liver Pathobiology on HCC Treatment Approach

February 1st 2020

The Importance of Combination Immune Therapy in Orthotopic Murine Glioblastoma

January 30th 2020

Connor Liu, medical student, Washington University School of Medicine, discusses the importance of combination immunotherapy in orthotopic murine glioblastoma.

Future Directions for Treatment of TNBC

January 22nd 2020

Neoadjuvant Treatment for Triple-Negative Breast Cancer

January 22nd 2020

Key Trials in R/R Metastatic TNBC

January 22nd 2020

IMpassion130 Trial: OS Updates in Metastatic TNBC

January 22nd 2020

Treating HER2+ mBC: Immunotherapy and TKIs

January 22nd 2020

Advanced HER2+ BC: Phase III HER2CLIMB and DESTINY-Breast01

January 22nd 2020

Emerging Agents for Treatment of Advanced HER2+ BC

January 22nd 2020

ATEMPT Trial: Stage I HER2+ Breast Cancer

January 22nd 2020

APHINITY Trial: Adjuvant HER2-Targeted Therapy in HER2+ BC

January 22nd 2020

Approaching HER2 Testing in Breast Cancer

January 22nd 2020

Hormone Receptor-Positive mBC: Neoadjuvant Therapy

January 22nd 2020

CtDNA Testing in Hormone Receptor-Positive mBC

January 22nd 2020